CMPS News & Analysis
2 articles
Market Mood
Compass Pathways (CMPS) Gets Buy Rating from H.C. Wainwright
Compass Pathways (CMPS) received a reiterated Buy rating from H.C. Wainwright. This endorsement indicates the firm's confidence in the company's future prospects. Analysts believe this rating may influence investment decisions and market movements for CMPS. Continued support from such firms is often seen as a positive signal for potential investors.
Read More
Compass Therapeutics (CMPS) Stock Price Target Cut Due to FDA Uncertainty
Stifel has reduced the stock price target for Compass Therapeutics (CMPS) amid ongoing uncertainty regarding FDA decisions. The specific new target price has not been disclosed in the article. This adjustment reflects concerns over regulatory timelines that could impact Compass's market valuation and future performance. Investors may view this downgrade as a signal to reassess risk associated with the company’s pipeline developments under FDA review.
Read More